BioAI Health, a US-based company involved in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, announces on Wednesday that it has added Jill Stefanelli, PhD as a new member to its advisory board of seasoned industry professionals.
In the new role, Dr Stefanelli will help drive commercial and corporate strategy for the company.
Dr Stefanelli has served as president, board member, and chief business officer at Paige, senior vice president of Partnerships at Invitae and various roles at other global diagnostic companies including Roche Diagnostics and Pacific Biosciences. She has served as senior scientist in the US Department of Agriculture's (USDA) Foreign Animal Disease Laboratory at Plum Island New York.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886